3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Benchmark H+,K+-ATPase Inhibitor for Gastric Acid Secretion Research

Executive Summary: 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) is a solid-phase compound with a molecular weight of 345.42 g/mol and a chemical formula of C₁₇H₁₉N₃O₃S, supplied at >98% purity by APExBIO [product details]. It exhibits potent H⁺,K⁺-ATPase inhibition (IC₅₀=5.8 μM), with pronounced antisecretory and antiulcer activities measured by its inhibition of histamine-induced acid formation (IC₅₀=0.16 μM) [DOI]. The compound is insoluble in water and ethanol but dissolves at ≥17.27 mg/mL in DMSO. For stability, -20°C storage is recommended, and it is not suitable for prolonged solution storage. This article reviews its biological rationale, mechanism, evidence, and workflow integration, contrasting its utility with related agents and clarifying its optimal experimental scope.

Biological Rationale

Gastric acid secretion is regulated by the H⁺,K⁺-ATPase proton pump in the parietal cells of the stomach. Dysregulation of this pathway underlies common gastric acid-related disorders, including peptic ulcer disease and gastroesophageal reflux disease (GERD) (Kong et al., 2025). Selective H⁺,K⁺-ATPase inhibitors are essential for dissecting the proton pump inhibition pathway and for modeling disease states in preclinical research. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, supplied by APExBIO, is an advanced tool in this space, offering improved potency over many legacy compounds. For more on the translational value of gastric acid inhibitors in neuro-gastrointestinal research, see this related article, which this review extends by providing protocol-level integration guidance.

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

This compound acts as a competitive inhibitor of the H⁺,K⁺-ATPase enzyme located on gastric parietal cells, thereby blocking the final step of gastric acid secretion. The molecule binds to the catalytic domain of the proton pump, preventing K⁺ exchange and subsequent H⁺ extrusion into the gastric lumen (Kong et al., 2025). This direct inhibition of acid formation is quantifiable by IC₅₀ values in cell-based assays. In histamine-induced acid secretion models, IC₅₀ is 0.16 μM, indicating high efficacy in inhibiting stimulated gastric acid output. Its selectivity reduces off-target effects in complex biological matrices, enabling precise pathway interrogation. For a technical comparison to legacy IC omeprazole analogs, see this protocol-focused article, which this review updates with new purity and assay compatibility data.

Evidence & Benchmarks

• In vitro, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide inhibits H⁺,K⁺-ATPase with an IC₅₀ of 5.8 μM (Kong et al. 2025, DOI:10.1111/ejn.70227).
• In histamine-induced acid secretion assays, it achieves an IC₅₀ of 0.16 μM, outperforming several comparator compounds (DOI:10.1111/ejn.70227).
• Compound purity is validated at approximately 98% by HPLC and NMR, supporting reproducibility in research workflows (product certificate).
• Solubility in DMSO is ≥17.27 mg/mL at ambient temperature, but the compound is insoluble in water and ethanol (APExBIO).
• Recommended storage at -20°C preserves compound stability for at least 12 months in solid form (APExBIO).
• Not suitable for diagnostic or clinical applications; intended for research use only (APExBIO).

For a scenario-driven comparison of workflow reproducibility and assay optimization, see this expert article; the present review provides updated solubility and purity parameters.

Applications, Limits & Misconceptions

This compound is primarily used in basic and translational research on gastric acid secretion and antiulcer activity. It serves as a control or experimental agent in peptic ulcer disease models, proton pump inhibition pathway studies, and high-throughput screening for antiulcer drug candidates. Its selectivity and potency distinguish it from generic IC omeprazole analogs, making it suitable for advanced mechanistic studies.

Common Pitfalls or Misconceptions

• Not intended for clinical or diagnostic use; safety and efficacy in humans are unestablished.
• Compound is unstable in solution at room temperature; avoid long-term storage in DMSO or other solvents.
• Insoluble in aqueous or ethanol media; improper solvents can lead to precipitation and assay failure.
• Not a direct anti-inflammatory or neuroprotective agent; its effects are limited to the gastric acid secretion pathway.
• Off-target effects may occur at concentrations above the validated IC₅₀ range; always titrate for experimental context.

Workflow Integration & Parameters

For optimal use, dissolve the compound in DMSO at concentrations up to 17.27 mg/mL. Aliquot and store at -20°C to minimize freeze-thaw cycles. Do not store working solutions beyond 24 hours at 4°C. For cell-based or ex vivo assays, dilute further in compatible buffers immediately before use. Employ validated HPLC or NMR protocols to confirm batch purity before critical experiments. For troubleshooting and advanced assay integration, this guide offers evidence-based workflow suggestions; this review extends those recommendations with updated shelf-life and solubility data.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) from APExBIO is a validated H⁺,K⁺-ATPase inhibitor, offering reproducible, high-purity performance for research in gastric acid secretion and antiulcer activity. It sets a new benchmark for proton pump inhibition pathway studies and is recommended for inclusion in advanced pharmacological and pathophysiological research on gastric acid-related disorders. For full technical details and ordering, consult the product page.